Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade

OncoImmunology

Volumn 5, Issue 12, 2016, Pages

  Eissler, Nina ^a   Mao, Yumeng ^a   Brodin, David ^a   Reuterswärd, Philippa ^b   Andersson Svahn, Helene ^b   Johnsen, John Inge ^a   Kiessling, Rolf ^a   Kogner, Per ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

Colony stimulating factor 1 receptor (CSF 1R) inhibition; myeloid cell repolarization; neuroblastoma; PD 1 checkpoint blockade; purinergic enzymes

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE A2 RECEPTOR; ANTIBODY; BLZ945; CD163 ANTIGEN; CD39 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; COLONY STIMULATING FACTOR RECEPTOR; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL ISOLATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FLOW CYTOMETRY; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MICROARRAY ANALYSIS; MONOCYTE; MOUSE; NATURAL KILLER CELL; NEUROBLASTOMA; NONHUMAN; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; WEIGHT REDUCTION;

EID: 84996605806     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1232222     Document Type: Article

References (54)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Canc 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
3. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Jr., Lao CD, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037):a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375-84; PMID:25795410; http://dx.doi.org/10.1016/S1470-2045(15)70076-8
4. Hanahan D, Weinberg RA. Hallmarks of cancer:the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
5. Mao Y, Poschke I, Kiessling R. Tumour-induced immune suppression:role of inflammatory mediators released by myelomonocytic cells. J Intern Med 2014; 276:154-70; PMID:24597954; http://dx.doi.org/10.1111/joim.12229
6. Mantovani A, Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med 2015; 212:435-45; PMID:25753580; http://dx.doi.org/10.1084/jem.20150295
7. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175
8. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015; 14:561-84; PMID:26228759; http://dx.doi.org/10.1038/nrd4591
9. Mao Y, Poschke I, Wennerberg E, Pico de Coana Y, Egyhazi Brage S, Schultz I, Hansson J, Masucci G, Lundqvist A, Kiessling R. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res 2013; 73:3877-87; PMID:23633486; http://dx.doi.org/10.1158/0008-5472.CAN-12-4115
10. Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R, Lundqvist A. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin Cancer Res 2014; 20:4096-106; PMID:24907113; http://dx.doi.org/10.1158/1078-0432.CCR-14-0635
11. Zelenay S, van der Veen AG, Bottcher JP, Snelgrove KJ, Rogers N, Acton SE, Chakravarty P, Girotti MR, Marais R. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 2015; 162:1257-70; PMID:26343581; http://dx.doi.org/10.1016/j.cell.2015.08.015
12. Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2014; 2:3; PMID:24829760; http://dx.doi.org/10.1186/2051-1426-2-3
13. Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, Cheng Y, Kim JW, Qiao J, Zhang L, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 2014; 20:5290-301; PMID:24691018; http://dx.doi.org/10.1158/1078-0432.CCR-14-0514
14. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 2013; 210:1389-402; PMID:23752227; http://dx.doi.org/10.1084/jem.20130066
15. Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, Hadjidaniel M, Liu CW, Metelitsa LS, Pique-Regi R, et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol 2012; 30:3525-32; PMID:22927533; http://dx.doi.org/10.1200/JCO.2011.40.9169
16. Carlson LM, Rasmuson A, Idborg H, Segerstrom L, Jakobsson PJ, Sveinbjornsson B, Kogner P. Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma. Carcinogenesis 2013; 34:1081-8; PMID:23349014; http://dx.doi.org/10.1093/carcin/bgt009
17. Santilli G, Piotrowska I, Cantilena S, Chayka O, D'Alicarnasso M, Morgenstern DA, Himoudi N, Pearson K, Anderson J, Thrasher AJ, et al. Polyphenon [corrected] E enhances the antitumor immune response in neuroblastoma by inactivating myeloid suppressor cells. Clin Cancer Res 2013; 19:1116-25; PMID:23322899; http://dx.doi.org/10.1158/1078-0432.CCR-12-2528
18. Cheung NK, Dyer MA. Neuroblastoma:developmental biology, cancer genomics and immunotherapy. Nature Rev Cancer 2013; 13:397-411; PMID:23702928; http://dx.doi.org/10.1038/nrc3526
19. Carlson LM, Kogner P. Neuroblastoma-related inflammation:may small doses of aspirin be suitable for small cancer patients? Oncoimmunology 2013; 2:e24658; PMID:24073359; http://dx.doi.org/10.4161/onci.24658
20. Mao Y, Eissler N, Le Blanc K, Johnsen JI, Kogner P, Kiessling R. Targeting suppressive myeloid cells potentiates checkpoint inhibitors to control spontaneous neuroblastoma. Clin Cancer Res 2016; 22:3849-59; PMID:26957560; http://dx.doi.org/10.1158/1078-0432.CCR-15-1912
21. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997; 16:2985-95; PMID:9214616; http://dx.doi.org/10.1093/emboj/16.11.2985
22. Rasmuson A, Segerstrom L, Nethander M, Finnman J, Elfman LH, Javanmardi N, Nilsson S, Johnsen JI, Martinsson T, Kogner P. Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma. PLoS One 2012; 7:e51297; PMID:23284678; http://dx.doi.org/10.1371/journal.pone.0051297
23. Rusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H, Chapman R, Hertzog PJ. Interferome v2.0:an updated database of annotated interferon-regulated genes. Nucleic Acids Res 2013; 41:D1040-6; PMID:23203888; http://dx.doi.org/10.1093/nar/gks1215
24. Liu L, Callahan MK, Huang D, Ransohoff RM. Chemokine receptor CXCR3:an unexpected enigma. Curr Top Dev Biol 2005; 68:149-81; PMID:16124999; http://dx.doi.org/10.1016/S0070-2153(05)68006-4
25. Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, Ku AW, Frelinger JG, Odunsi K, Gajewski TF, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun 2015; 6:7458; PMID:26109379; http://dx.doi.org/10.1038/ncomms8458
26. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33:1974-82; PMID:25605845; http://dx.doi.org/10.1200/JCO.2014.59.4358
27. Munn DH, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol 2015; 39:1-6; PMID:26609943; http://dx.doi.org/10.1016/j.coi.2015.10.009
28. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58:49-59; PMID:18446337; http://dx.doi.org/10.1007/s00262-008-0523-4
29. Khaled YS, Ammori BJ, Elkord E. Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients. J Immunol Res 2014; 2014:879897; PMID:24741628; http://dx.doi.org/10.1155/2014/879897
30. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506
31. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013; 19:1264-72; PMID:24056773; http://dx.doi.org/10.1038/nm.3337
32. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Canc Cell 2014; 25:846-59; PMID:24898549; http://dx.doi.org/10.1016/j.ccr.2014.05.016
33. Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 2014; 74:5057-69; PMID:25082815; http://dx.doi.org/10.1158/0008-5472.CAN-13-3723
34. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res 2012; 72:5209-18; PMID:22915761; http://dx.doi.org/10.1158/0008-5472.CAN-12-1187
35. Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, Schell MJ, Sondak VK, Weber JS, Mulé JJ. 12-Chemokine gene signature identifies lymph node-like structures in melanoma:potential for patient selection for immunotherapy? Sci Rep 2012; 2:765; PMID:23097687; http://dx.doi.org/10.1038/srep00765
36. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance:prognostic, predictive, and mechanistic signatures. Immunity 2013; 39:11-26; PMID:23890060; http://dx.doi.org/10.1016/j.immuni.2013.07.008
37. Stoll G, Enot D, Mlecnik B, Galon J, Zitvogel L, Kroemer G. Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. Oncoimmunology 2014; 3:e27884; PMID:24790795; http://dx.doi.org/10.4161/onci.27884
38. Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, Dumur C, Wang E, Ramakrishnan V, Wang XY, et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat 2012; 131:871-80; PMID:21479927; http://dx.doi.org/10.1007/s10549-011-1470-x
39. Pico de Coana Y, Poschke I, Gentilcore G, Mao Y, Nystrom M, Hansson J, Masucci GV, Kiessling R. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res 2013; 1:158-62; PMID:24777678; http://dx.doi.org/10.1158/2326-6066.CIR-13-0016
40. Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, Holland-Letz T, Umansky L, Beckhove P, Sucker A, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res 2015; 21:5453-9; PMID:26289067; http://dx.doi.org/10.1158/1078-0432.CCR-15-0676
41. Martens A, Wistuba-Hamprecht K, Geukes Foppen MH, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 2016; 22:2908-18; PMID:26787752; http://dx.doi.org/10.1158/1078-0432.CCR-15-2412
42. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563-7; PMID:25428504; http://dx.doi.org/10.1038/nature14011
43. Pinton L, Solito S, Damuzzo V, Francescato S, Pozzuoli A, Berizzi A, Mocellin S, Rossi CR, Bronte V, Mandruzzato S. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. Oncotarget 2016; 7:1168-84; PMID:26700461
44. Fretier S, Besse A, Delwail A, Garcia M, Morel F, Leprivey-Lorgeot V, Wijdenes J, Praloran V, Lecron JC. Cyclosporin A inhibition of macrophage colony-stimulating factor (M-CSF) production by activated human T lymphocytes. J Leukoc Biol 2002; 71:289-94; PMID:11818450
45. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8:533-44; PMID:18551128; http://dx.doi.org/10.1038/nri2356
46. Bianchi G, Vuerich M, Pellegatti P, Marimpietri D, Emionite L, Marigo I, Bronte V, Di Virgilio F, Pistoia V, Raffaghello L. ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. Cell Death Dis 2014; 5:e1135; PMID:24651438; http://dx.doi.org/10.1038/cddis.2014.109
47. Antonioli L, Blandizzi C, Pacher P, Hasko G. Immunity, inflammation and cancer:a leading role for adenosine. Nat Rev Cancer 2013; 13:842-57; PMID:24226193; http://dx.doi.org/10.1038/nrc3613
48. Allard B, Pommey S, Smyth MJ, Stagg J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res 2013; 19:5626-35; PMID:23983257; http://dx.doi.org/10.1158/1078-0432.CCR-13-0545
49. Hatfield SM, Kjaergaard J, Lukashev D, Schreiber TH, Belikoff B, Abbott R, Sethumadhavan S, Philbrook P, Ko K, Cannici R, et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med 2015; 7:277ra30; PMID:25739764; http://dx.doi.org/10.1126/scitranslmed.aaa1260
50. Mittal D, Young A, Stannard K, Yong M, Teng MW, Allard B, Stagg J, Smyth MJ. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res 2014; 74:3652-8; PMID:24986517; http://dx.doi.org/10.1158/0008-5472.CAN-14-0957
51. Kocak H, Ackermann S, Hero B, Kahlert Y, Oberthuer A, Juraeva D, Roels F, Theissen J, Westermann F, Deubzer H, et al. Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma. Cell Death Dis 2013; 4:e586; PMID:23579273; http://dx.doi.org/10.1038/cddis.2013.84
52. Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, Matthay K, Buckley J, Ortega A, Seeger RC. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 2006; 98:1193-203; PMID:16954472; http://dx.doi.org/10.1093/jnci/djj330
53. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012; 483:589-93; PMID:22367537; http://dx.doi.org/10.1038/nature10910
54. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus:NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002; 30:207-10; http://dx.doi.org/10.1016/S0076-6879(06)11019-8